Neurogenic Dysphonia/Dysphagia Registry

Merz North America, Inc.146 enrolled

Overview

The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be obtained during usual care of patients with dysphonia/dysphagia treated with vocal fold augmentation.

The Neurogenic Dysphonia/Dysphagia Registry is a 510K post-clearance multicenter, observational, open-label registry of the benefits and risks of management and outcomes of patients with neurogenic dysphonia/dysphagia who have received vocal fold augmentation (VFA). Enrollment is open to all eligible patients meeting all of the inclusion and none of the exclusion criteria, with a target of 400 patients. Up to 100 sites in the US and abroad will be a part of the registry. Sites will provide retrospective data for active patients who have undergone VFA within the past 24 months at the site and also begin to prospectively enroll patients who are receiving VFA as a part of their usual care. Patients will be followed for up to five years prospectively, until lost to follow-up, or death.

Study Type

OBSERVATIONAL

Enrollment

146

Conditions

Neurogenic Dysphonia Neurogenic Dysphagia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and Females, ≥18 years of age * Diagnosis of neurogenic dysphonia/dysphagia * Under active treatment with VFA and follow-up care Exclusion Criteria: • Patients with: * Vocal fold scar * Laryngeal cancer defect * Irradiation to the larynx * Laryngeal trauma * End-stage cancer

Locations (12)

Merz Clinical Site

La Jolla, California, United States

Merz Clinical Site

Sacramento, California, United States

Merz Clinical Site

Augusta, Georgia, United States

Outcomes

Primary Outcomes

Collect and characterize the different types (and frequency) of initial assessments/evaluations performed on patients.

Characterize the initial assessment (e.g. types of assessments/evaluations performed and severity of voice, swallowing, cough as determined by patient reported outcomes where available)

Time frame: 1 day

Collect and characterize the different types (and frequency) of subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment

Characterize subsequent management of neurogenic dysphonia/dysphagia patients who receive VFA in terms of product used, evaluations performed and referrals and recommendations for further treatment

Time frame: 5 years

Secondary Outcomes

Collect patient reported outcomes (PRO) and clinician assessments to characterize voice, swallowing, and cough outcomes post-injection

Characterize voice, swallowing, and cough outcomes post-injection, as determined by patient reported outcomes (PRO) and clinician assessment, as well as select adverse events/complications of interest, associated with use of VFA products in patients with neurogenic dysphonia/dysphagia, including in patients with multiple injections

Time frame: 5 years

Collect types and frequency of different patient characteristics and medical care practices associated with improved health outcomes after VFA

Identify patient characteristics and medical care practices associated with improved health outcomes after VFA

Time frame: 5 years

Collect and measure information on the duration of effect of Prolaryn products and the need for re-injection

Assess and measure the duration of effect of Prolaryn products

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.